Laboral Kutxak jakinarazi du erraz gainditu dituela Espainiako Bankuak finantza erakundeei ipini dizkien kapital-eskakizunak.
Espainiako Bankuaren arabera, %10,25ekoa da Common Equity Tier 1 (CET1) izeneko lehen mailako kapitalaren gutxieneko ratioa Euskal Herriko kooperatiba honentzat; halaxe jaso da arautzaileak egindako ikuskaritzako berrikuspen- eta ebaluazio-prozesuaren (SREParen) emaitzetan.
Spend a minute or two on the Internet, and you’ll find 3D printing can be used to build all sorts of things: automobile parts and prototypes, prosthetic ears, stem cells, submachine guns, eyeglasses, and even desserts customized to one’s nutritional requirements.
But what about building construction? Why couldn’t these same methods be adapted to build actual-scale civil structures—single-family homes, commercial buildings, even large settlements—with greater speed and efficiency?
A House in 20 Hours. That was just what Behrokh Khoshnevis says he envisioned when developing Contour Crafting (CC), a 3D concrete-extruding printer that can be used to build a single 2,500-square-foot house in about 20 hours.
The wealth management industry has been facing a number of profound challenges after the financial crisis, making it difficult to serve the needs of HNWIs. A combination of structural and cyclical headwinds has put significant pressure on revenues, margins, and costs, leading to the emergence of trends aimed at augmenting revenues and controlling costs. This document provides a high-level analysis of the top 10 wealth management trends that are expected to impact the wealth management industry in 2016.
Keith Joung, a scientist at Massachusetts General Hospital in Boston, and his colleagues say they have come up with a way to make the gene editing system known as CRISPR-Cas9 far more precise when it enters cells to snip DNA.
But as Joung, who is also a founder of Cambridge, MA-based gene editing company Editas Medicine, was quick to note, there’s much more work to do to prove the technique makes CRISPR-Cas9 precise enough—and safe enough—to speed up the already competitive race to test CRISPR-based therapeutics in humans.
There are a slew of gene therapy companies trying to develop a long-lasting, perhaps even permanent treatment for hemophilia. The proof that these companies can really make an impact on the disease will come out in dribs and drabs from clinical trials over the next several years, and today, one of them, Dutch firm UniQure, did so with some promising early results.
In pursuit of environmentally friendly fossil fuel alternatives, corn, soybeans and palm oil have been converted into biofuels to power vehicles, factories and even the trains at Disneyland. Yet, these sources of energy, though far less polluting than petroleum or coal, occupy arable land, and may further jeopardize the global food supply.
Now, Israeli researchers have investigated the possibility of producing fuel from sea-harvested algae, and have found that a certain strain could provide an alternative fuel source, while restoring marine life in contaminated areas.
This year has so far shaped up to be a breakout year for healthcare investing, with over $6B invested and deep-pocketed hedge funds and mutual funds increasingly involved in deals.
Pharmaceutical corporations are also playing a huge role in this space, with many pharma companies effectively outsourcing the R&D of some newer and experimental drugs to smaller, more nimble companies by investing in them.
In industrialized countries, a particularly high number of people suffer from arteriosclerosis -- with fatal consequences: Deposits in the arteries lead to strokes and heart attacks. A team of researchers under the leadership of the University of Bonn has now developed a method for guiding replacement cells to diseased vascular segments using nanoparticles. The scientists demonstrated in mice that the fresh cells actually exert their curative effect in these segments. However, much research remains to be done prior to use in humans. The results are now being published in the journal ACS NANO.
Fully functional pancreatic cells have been cultured by scientists, potentially meaning the end of daily insulin injections for sufferers of the disease. The lab-made cells were tested in mice, and they successfully prevented the mice from developing diabetes.
The new research will mean that pancreatic cells can be developed to match each individual diabetes patient's DNA. This is the first time fully working pancreatic cells have been developed successfully in a lab, a breakthrough for diabetes research.
The latest machine-learning techniques promise to transform whole industries by making it easier for computers to recognize patterns in data, to make accurate predictions, and to generally behave more intelligently. Unfortunately, the experts capable of crafting and optimizing the code needed to make this magic possible are in pretty short supply.
